BridgeBio Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BridgeBio Pharma generated cash of -$527,720,000, which is less than the previous year. Cash used in financing activities reached the amount of $451,535,000 last year. Net change in cash is therefore -$22,152,000.
Cash Flow
| 2017 | -40.48M | -464K | 112.98M |
|---|---|---|---|
| 2018 | -136.64M | -21.03M | 501.54M |
| 2019 | -253.58M | -217.25M | 398.79M |
| 2020 | -399.71M | -52.99M | 447.18M |
| 2021 | -497.93M | -200.82M | 736.44M |
| 2022 | -419.49M | 453.14M | -13.13M |
| 2023 | -527.72M | 54.03M | 451.53M |
BBIO Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 416.88M | 396.36M | 358.67M | 364.19M | 436.24M | 92.37M | 20.34M |
Operating activities | |||||||
Net income | -643.20M | -484.65M | -586.45M | -505.48M | -288.58M | -169.45M | -43.83M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 6.49M | 6.77M | 5.84M | 3.08M | 859K | 245K | 260K |
Stock-based compensation expense | 0 | 91.55M | 99.50M | 58.45M | 21.37M | 0 | 1.84M |
| Deferred income tax benefit | 0 | 91.55M | 99.50M | 58.45M | 21.37M | 0 | 1.84M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 15.32M | 15.16M | -19.74M | 2.84M | -2.84M | 0 | 0 |
Inventories | 0 | -15.16M | 19.74M | -2.84M | 2.84M | 0 | 0 |
Accounts payable | 2.78M | -349K | 2.83M | -735K | -4.65M | 16.7M | 1.57M |
Cash generated by operating activities | -527.72M | -419.49M | -497.93M | -399.71M | -253.58M | -136.64M | -40.48M |
Investing activities | |||||||
Purchases Of Investments | -137.26M | -193.05M | -643.27M | -287.85M | -212.89M | 0 | 0 |
Investments In Property Plant And Equipment | -1.30M | -6.32M | -48.24M | -7.51M | -5.13M | -18.17M | -464K |
Acquisitions Net | 0 | 120M | -35M | 21.24M | -5.49M | -2.85M | 2.83M |
Cash generated by investing activities | 54.03M | 453.14M | -200.82M | -52.99M | -217.25M | -21.03M | -464K |
Financing activities | |||||||
Common Stock Issued | 449.81M | 4.85M | 3.82M | 1.20M | 366.23M | 95.53M | 107.16M |
Payments for dividends | 0 | 0 | 0 | 0 | -997K | 0 | -1.15M |
Repurchases of common stock | -6.88M | -1.56M | -204.74M | -75.71M | 0 | 0 | 0 |
Repayments of term debt | 0 | -20.48M | -124.11M | -536.96M | 36.93M | -1.09M | 4.13M |
Cash used in financing activities | 451.53M | -13.13M | 736.44M | 447.18M | 398.79M | 501.54M | 112.98M |
Net Change In Cash | -22.15M | 20.51M | 37.68M | -5.51M | -72.04M | 343.86M | 72.03M |
Cash at end of period | 394.73M | 416.88M | 396.36M | 358.67M | 364.19M | 436.24M | 92.37M |
| Data source | Data source | Data source | Data source | Data source |